Dr. Shah on the Future of CAR T-Cell Therapy in Multiple Myeloma

Video

Nina Shah, MD, discusses the future of CAR T-cell therapy in multiple myeloma. 

Nina Shah, MD, associate professor of medicine, Department of Medicine, at the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discusses the future of CAR T-cell therapy in multiple myeloma. 

In July 2020, a biologics license application was resubmitted to the FDA for the BCMA-directed CAR T-cell therapy idecabtagene vicleucel (ide-cel; bb2121) for the treatment of patients with relapsed/refractory multiple myeloma. 

To date, most clinical trials evaluating CAR T-cell therapy have included patients who have heavily pretreated, relapsed/refractory disease, explains Shah. However, inclusion criteria ​typically require ​patients to have had 3 ​prior lines of treatment ​and have progressing disease.

​Although investigational agents in the pipeline could lead to ​novel combination regimens in the near future​, enrollment in clinical trials remains a critical option for patients, Shah concludes.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Prerna Mewawalla, MD, medical director of Apheresis and a hematologist-oncologist in the Division of Hematology and Cellular Therapy at Allegheny Health Network, as well as an associate professor at the Drexel University College of Medicine
Surbhi Sidana, MD, an assistant professor of medicine, bone marrow transplantation, and cellular therapy at Stanford
Damien Maura, PhD, a senior scientist at Voyager Therapeutics
© 2025 MJH Life Sciences

All rights reserved.